The South African national HIV program has achieved substantial antiretroviral therapy (ART) coverage over the last decade, reaching 56% of all human immunodeficiency virus (HIV)--infected people in 2016, with 3.8 million adults on treatment \[[@CIT0001]\]. Coverage expansion has been supported by a national strategic plan for prevention, treatment, care, support, and surveillance linked with policy \[[@CIT0002]\] and guideline changes allowing for earlier ART initiation \[[@CIT0003]\]. As ART scale-up continues, it is anticipated that increased access to treatment and reduced stigma will lead to treatment initiation earlier in HIV infection. Numerous studies have shown, both in South Africa \[[@CIT0007]\] and elsewhere \[[@CIT0008]\], that those who initiate ART at higher CD4 cell counts can expect a near-normal life expectancy and are at dramatically reduced risk of onward HIV transmission \[[@CIT0011]\]. In contrast, a CD4 count \<200 cells/µL is a strong predictor of severe morbidity, comorbidities such as tuberculosis and cryptococcal meningitis, and mortality \[[@CIT0012], [@CIT0013]\]. Guidelines for managing advanced HIV disease and rapid initiation of ART have been published recently \[[@CIT0014]\].

Despite efforts to promote earlier treatment initiation, limited data are available on the existing burden of advanced HIV disease in South Africa and trends over time. Recent analysis of unlinked laboratory CD4 results suggests that the proportion of patients with advanced (CD4 \<200 cells/µL) and very advanced (CD4 \<100 cells/µL) HIV disease remains high \[[@CIT0015]\], despite advances in access to and increased enrollment into care in recent years. Furthermore, an average of 10% of annual CD4 samples tested in the South African National Health Laboratory Service (NHLS) have a CD4 count \<100 cells/µL, with a corresponding reported national positivity rate for cryptococcal antigenemia of 4%--5% \[[@CIT0016], [@CIT0017]\]. Because these CD4 samples are obtained from patients both prior to and after ART initiation, and because patients may have multiple records, it is difficult to make inferences from these unlinked CD4 data about the prevalence of advanced HIV among patients seeking care.

The aim of this study was to assess the distribution of ART-naive patients presenting with advanced and very advanced HIV disease, as indicated by a CD4 count \<200 cells/µL and \<100 cells/µL, respectively, and identify changes in distribution patterns over the last 10 years of scale-up of care.

METHODS {#s5}
=======

The NHLS, being the sole provider of CD4 testing for the South African public sector since the onset of the HIV program, performed \>3 million tests per year through a network of between 50 and 60 CD4 testing laboratories. These CD4 laboratory data can provide insights into the immunological status of patients in HIV care and can be used to identify trends and changes in the prevalence of advanced HIV disease over time. Historically, in the absence of a unique patient identifier, specimen-based laboratory data has been largely unable to differentiate between CD4 testing among those starting ART and those already on ART and being monitored during follow-up. We linked CD4 count and viral load monitoring tests taken from 1 April 2004 to 31 December 2016 using probabilistic linking methods adapted from the Fellegi-Sunter method \[[@CIT0018], [@CIT0019]\], based upon patient characteristics: name, surname, birth date, gender, facility, and province. We calculated a similarity score for each test as a weighted average over component scores, with weights optimized using manually matched training data taking into account the response frequency (rare elements are weighted more than common ones), adjusting for spelling differences in names using the Jaro-Winkler approach \[[@CIT0018], [@CIT0020]\], and inversions in names, and date elements. Compared against a manually matched gold standard, we found a sensitivity of 91.0% (ie, 9.0% undermatching) and positive predictive value of 90.5% (ie, 9.5% overmatching). Our primary outcome was entry into HIV clinical care as defined by a patient's first CD4 count. To ensure that the CD4 tests included in the analysis were taken prior to ART initiation, we excluded patients who had either (1) a viral load test earlier than 30 days before the first CD4 test regardless of the viral load result or (2) a suppressed viral load result (\<1000 copies/mL) within 30 days prior or 60 days after the first CD4 count test.

We included all patients aged ≥15 years as CD4 tests were less consistently used to determine treatment eligibility in the pediatric population and were considered to be a poor indicator of entry into care. We only included patients from the province of KwaZulu-Natal (KZN) from 1 July 2011 onward as the province did not start contributing tests to the NHLS until the second quarter of 2010.

We estimated numbers and proportions of patients with first CD4 counts of \<100 cells/µL and 100--199 cells/µL for 12-month periods from 1 January 2005 to 31 December 2016. We calculated relative risk and 95% confidence intervals (CIs) to show differences in the proportion of patients presenting with advanced disease by sex. All analysis was conducted using SAS version 9.4 software (SAS Institute, Cary, North Carolina).

RESULTS {#s6}
=======

People Living With HIV Entering Care From 2005 to 2016 {#s7}
------------------------------------------------------

The probabilistic linking method yielded an estimated total number of adults (males and females \>15 years) with a first CD4 test to be 8036919 ([Table 1](#T1){ref-type="table"}). The number of patients with a first CD4 increased steadily from 344189 in 2005 to a peak of 903118 in 2012 and then declining to 654868 in 2016. Of the total number of patients entering care from 2005 to 2016, 65% were females.

###### 

Adult Females, Adult Males, and All Adults With First CD4 Count Test \<100 or 100--199 Cells/µL, by Sex and Calendar Year of Test, South Africa

  Year        Females          Males            Total     RR (95% CI) of Males With First CD4 Count 0--199 Cells/µL Compared to Females                                                                            
  ----------- ---------------- ---------------- --------- ------------------------------------------------------------------------------- ---------------- --------- ----------------- ----------------- --------- -------------------
  2005        24.4% (56409)    18.4% (42395)    230985    34.3% (38850)                                                                   20.0% (22597)    113204    27.7% (95259)     18.9% (64992)     344189    1.27 (1.26--1.28)
  2006        22.6% (71024)    18.0% (56714)    314713    33.7% (48608)                                                                   20.0% (28849)    144110    26.1% (119633)    18.6% (85564)     458823    1.32 (1.32--1.33)
  2007        20.9% (74618)    17.4% (61978)    356259    32.9% (52720)                                                                   19.9% (32011)    160471    24.6% (127338)    18.2% (93989)     516730    1.38 (1.37--1.39)
  2008        19.7% (84757)    17.7% (76224)    429455    32.3% (62948)                                                                   20.6% (40167)    194682    23.7% (147706)    18.6% (116391)    624137    1.41 (1.41--1.42)
  2009        17.3% (74291)    17.0% (72826)    428413    29.7% (59743)                                                                   20.4% (41065)    201298    21.3% (134034)    18.1% (113891)    629711    1.46 (1.45--1.47)
  2010        16.2% (82834)    17.2% (88324)    512650    27.7% (69041)                                                                   20.7% (51623)    249265    19.9% (151875)    18.4% (139947)    761915    1.45 (1.44--1.46)
  2011        14.4% (84913)    16.1% (95158)    590823    25.2% (78334)                                                                   20.2% (62930)    310888    18.1% (163248)    17.5% (158088)    901711    1.49 (1.48--1.50)
  2012        14.0% (81201)    15.3% (89138)    581462    24.9% (80096)                                                                   19.9% (63965)    321656    17.9% (161297)    17.0% (153103)    903118    1.53 (1.52--1.54)
  2013        13.0% (65050)    14.1% (70383)    498888    23.9% (69523)                                                                   19.1% (55601)    291487    17.0% (134573)    15.9% (125984)    790375    1.58 (1.57--1.59)
  2014        12.8% (58940)    13.8% (63329)    459105    23.6% (66748)                                                                   18.9% (53544)    282794    16.9% (125688)    15.8% (116873)    741899    1.60 (1.59--1.61)
  2015        12.4% (53728)    13.6% (59006)    432661    22.8% (63104)                                                                   19.0% (52561)    276782    16.5% (116831)    15.7% (111567)    709443    1.60 (1.59--1.62)
  2016        12.6% (49603)    13.9% (54666)    392770    23.1% (60421)                                                                   19.3% (50472)    262098    16.8% (110024)    16.1% (105138)    654868    1.59 (1.58--1.61)
  All years   16.0% (837369)   15.9% (830142)   5228184   26.7% (750137)                                                                  19.8% (555384)   2808735   19.8% (1587506)   17.2% (1385526)   8036919   

Data are presented as % (No.) unless otherwise indicated.

Abbreviations: CI, confidence interval; RR, relative risk.

Proportion of Adults Entering Care With Advanced Disease {#s8}
--------------------------------------------------------

From 2005 to 2016, the proportion of patients with a CD4 count of \<200 cells/µL entering into care declined from 46.6% to 32.9% ([Figure 1](#F1){ref-type="fig"}). However, from 2012 to 2016 the proportion of patients presenting with advanced HIV disease remained relatively unchanged and ranged from 34.8% to 32.9%. The proportion of patients presenting with very advanced HIV disease (CD4 \<100 cells/µL) fell from 27.7% in 2005 to 18.1% in 2011, but has remained unchanged over the last 5 years, at 16.8% in 2016.

![Proportion of patients entering care with advanced and very advanced HIV disease (first CD4 count test \<100 and 100--199 cells/µL).](ciy04501){#F1}

Proportion of Advanced HIV Disease Among Males and Females {#s9}
----------------------------------------------------------

Between 2005 and 2016, the proportion of males presenting with advanced disease was consistently higher than the proportion of females presenting with advanced disease. However, the share presenting with advanced disease also fell faster for females over this period. Among males seeking care, the share with CD4 \<200 cells/µL fell just 11 percentage points, from 54.3% in 2005 to 42.3% in 2016. In contrast, among women seeking care, the share with CD4 \<200 cells/µL fell by 16 percentage points, from 42.8% in 2005 to 26.5% by 2016 ([Figure 2](#F2){ref-type="fig"}), the male--female gap widening by nearly 50%. From 2012 to 2016, the proportion of all males with a first CD4 \<100 cells/µL was close to double that among females with CD4 \<100 cells/µL ([Figure 2](#F2){ref-type="fig"}). The relative risk of males presenting with a first CD4 count of \<100 cells/µL was 1.27 (95% CI, 1.26--1.28) in 2005 and has increased to 1.59 (95% CI, 1.58--1.61) in 2016 ([Table 1](#T1){ref-type="table"}). The excess burden of advanced and very advanced disease among males (vs females) was apparent in all age groups in 2016 ([Figure 3](#F3){ref-type="fig"}).

![Proportion of males and females presenting to care with advanced and very advanced HIV disease from 2005 to 2016 (CD4 values presented as cells/µL).](ciy04502){#F2}

![Distribution by age (in years) and sex of the proportions of first CD4 count test \<100 and 100--199 cells/µL in 2016.](ciy04503){#F3}

DISCUSSION {#s10}
==========

The number of people receiving ART through the South African national HIV program has increased 30-fold, from 103300 in 2005 to 3.8 million in 2016 \[[@CIT0001]\]. Since the inception of the program, CD4 counts have been provided nationally, initially to guide treatment initiation decisions, as per World Health Organization guideline thresholds, and more recently to identify those with advanced HIV disease and therefore at higher risk for morbidity, mortality, and with greater medical need.

We found that while the proportion of patients presenting with advanced HIV disease has declined over the 12 years, it has remained unchanged over the last 5 years, with more than a third of patients entering care with a CD4 cell count \<200 cells/µL. The absence of clinical symptoms suggestive of deteriorating health and the lack of incentives to be tested in an environment where stigma associated with HIV infection is still prevalent have contributed to maintaining the status quo. The persistently high burden of patients presenting with advanced HIV disease represents a substantial and avoidable burden of HIV morbidity, increased medical costs, and increased risk of onward transmission.

Our work is consistent with data from other reports from both high-income settings \[[@CIT0021]\] and low- and middle-income settings, elsewhere \[[@CIT0021]\] and in South Africa \[[@CIT0015]\], which reported a general increase in average CD4 cell count at presentation and at initiation of ART. These gains are due in part to changes in policies supporting earlier access to treatment and improvements in drug efficacy and tolerability as well as formulation. Nevertheless, despite these gains, there is a persistent burden of patients who present late for care with advanced HIV disease. Furthermore, the sex disparities consistently increased over the study period, with the relative risk of males entering into care with advanced disease increasing in the later years. This concurs with the findings from 4 sub-Saharan countries, where the odds of advanced HIV disease at ART initiation were also higher among men and increased over time \[[@CIT0024]\]. There are several factors that have resulted in these differences. The rapid ART scale-up has focused on women and children, supported by high-level political commitment \[[@CIT0025]\] and funding \[[@CIT0026]\]. Consequently, more women and children have accessed care and treatment and have done so earlier than men, who only contributed to 35% of those enrolled in ART programs \[[@CIT0027]\]. This is further augmented by poor health-seeking behavior of HIV-positive men \[[@CIT0028]\]. Therefore, ART programs will need to continue identifying barriers to access care and devise strategies to overcome them, as well as to ensure equitable access for both men and women.

These findings highlight the need to focus on access to rapid diagnosis and linkage to care, particularly among men, to support early identification and accelerated ART initiation. Nevertheless, it can be expected that even with continued improvements in early access to testing and treatment, a high proportion of patients will continue to present with advanced HIV disease. In addition, there is some evidence of an increasing number of patients presenting with advanced HIV disease following initiation and subsequent interruption of ART \[[@CIT0029]\]. For such patients, the ability to identify advanced HIV disease---and therefore, vulnerability to severe morbidity and mortality---is critical to management of their infection and its sequelae. In the age of "Treat all," CD4 testing remains essential to identify patients presenting with advanced disease and to tailor care to their needs.

The study has several strengths and limitations. The analysis presented here is based on a large nationally representative database from patients accessing the public-sector healthcare services and spans \>12 years. The NHLS database does not include patients who seek access to clinical care in the private sector or some nongovernmental organizations; care utilization outside the public sector was estimated to be 8.5% in 2015 \[[@CIT0030]\]. ART monitoring laboratories from KZN were not initially part of the NHLS network of laboratories, and patients from KZN were not included in our analysis until Q2 2011. Therefore, the results prior to that date do not represent the entire national population. In the absence of a unique patient identifier in South Africa, laboratory tests have been probabilistically linked with acceptable level of sensitivity and specificity. Still, linkage errors may have occurred, which could lead us to over- or underestimate the numbers of patients seeking care. We note that our estimate of \>8 million patients includes all patients who presented to the public-sector HIV program and had blood drawn for a CD4 count, regardless of whether they were linked to further care and treatment. Our data also include patients who sought care in the early years of the program and may no longer be alive. We acknowledge that some contribution to the sex disparities likely originated from pregnant females, who have had additional opportunities to access care and be offered early HIV testing. However, estimates from a multicenter cohort study of adult patients initiating ART in South Africa reported only 7% of females to be pregnant \[[@CIT0031]\]. Correction for this source of bias was not possible because the pregnancy status is not available in the NHLS database. Finally, our analysis was limited to first time care-seekers and did not assess the burden of advanced HIV disease among patients who have started ART, disengaged from care, and subsequently returned to care when they are sick. Therefore, our results are likely partial estimates of the total burden of advanced HIV disease in South Africa.

In conclusion, these findings show an enduring and substantial burden of advanced HIV disease, despite a period of intense scale-up of ART access. In addition to promoting earlier care-seeking, there is a continued need to be able to identify patients with advanced HIV disease and to target this population with an appropriate package of care and services to address the high risk of morbidity and mortality they face, as recently recommended by the World Health Organization.
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